TABLE 3

Pharmacokinetic parameters for and analysis of tafenoquine following administration of tafenoquine with or without dihydroartemisinin-piperaquine or artemether-lumefantrinea

Analyte and treatment group or parameterGeometric mean AUC0–∞ (ng · h/ml)Geometric mean AUC0–last (ng · h/ml)Geometric mean Cmax (ng/ml)Geometric mean t1/2 (h)Median Tmax (h) (range)
Tafenoquine
    TQ + DHA-PQP (n = 24)109,333.793,809.3274.7483.96.0 (6.0–23.0)
    TQ (n = 24)97,195.588,283.9199.6375.212.1 (6.0–72.0)
    CVb (%)23.421.620.716.3
    GMR (90% CI)1.12 (1.01, 1.26)1.06 (0.96, 1.18)1.38 (1.25, 1.52)1.29 (1.19, 1.40)
Tafenoquine
    TQ + AL (n = 22)102,328.491,119.3208.4396.512.1 (2.0–60.0)
    TQ (n = 24)97,195.588,283.9199.6375.212.1 (6.0–72.0)
    CVb (%)26.224.119.915.5
    GMR (90% CI)1.05 (0.93, 1.20)1.03 (0.92, 1.16)1.04 (0.95, 1.15)1.06 (0.98, 1.14)
  • a CVb, between-subject variability; GMR, geometric mean ratio.